These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 23686786)

  • 21. Plasma leptin and insulin levels in weight-reduced obese women with normal body mass index: relationships with body composition and insulin.
    Guven S; El-Bershawi A; Sonnenberg GE; Wilson CR; Hoffmann RG; Krakower GR; Kissebah AH
    Diabetes; 1999 Feb; 48(2):347-52. PubMed ID: 10334312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.
    Nørregaard J; Jørgensen S; Mikkelsen KL; Tønnesen P; Iversen E; Sørensen T; Søeberg B; Jakobsen HB
    Clin Pharmacol Ther; 1996 Dec; 60(6):679-86. PubMed ID: 8988071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
    Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
    Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA; Stentz F; Gettys T; Smith SR
    Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of an herbal dietary supplement containing ephedrine and caffeine on oxygen consumption in humans.
    Greenway FL; Raum WJ; DeLany JP
    J Altern Complement Med; 2000 Dec; 6(6):553-5. PubMed ID: 11152061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic ephedrine administration decreases brown adipose tissue activity in a randomised controlled human trial: implications for obesity.
    Carey AL; Pajtak R; Formosa MF; Van Every B; Bertovic DA; Anderson MJ; Eikelis N; Lambert GW; Kalff V; Duffy SJ; Cherk MH; Kingwell BA
    Diabetologia; 2015 May; 58(5):1045-54. PubMed ID: 25725625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study.
    Kwak JH; Ahn CW; Park SH; Jung SU; Min BJ; Kim OY; Lee JH
    Food Funct; 2012 Oct; 3(10):1019-24. PubMed ID: 22739624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leptin levels are associated with fat oxidation and dietary-induced weight loss in obesity.
    Verdich C; Toubro S; Buemann B; Holst JJ; Bülow J; Simonsen L; Søndergaard SB; Christensen NJ; Astrup A
    Obes Res; 2001 Aug; 9(8):452-61. PubMed ID: 11500525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperleptinemia in obese adolescents deregulates neuropeptides during weight loss.
    Dâmaso AR; de Piano A; Sanches PL; Corgosinho F; Tock L; Oyama LM; Tock L; do Nascimento CM; Tufik S; de Mello MT
    Peptides; 2011 Jul; 32(7):1384-91. PubMed ID: 21641948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.
    Bhasin S; Parker RA; Sattler F; Haubrich R; Alston B; Umbleja T; Shikuma CM;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1049-57. PubMed ID: 17164307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is an ephedrine caffeine treatment contraindicated in hypertension?
    Ingerslev J; Svendsen TL; Mørk A
    Int J Obes Relat Metab Disord; 1997 Aug; 21(8):666-73. PubMed ID: 15481766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity.
    Daly PA; Krieger DR; Dulloo AG; Young JB; Landsberg L
    Int J Obes Relat Metab Disord; 1993 Feb; 17 Suppl 1():S73-8. PubMed ID: 8384187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese.
    Dulloo AG; Miller DS
    Nutrition; 1989; 5(1):7-9. PubMed ID: 2520262
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulation of adipsin and body composition in the monosodium glutamate (MSG)-treated mouse.
    Spurlock ME; Hahn KJ; Miner JL
    Physiol Behav; 1996 Nov; 60(5):1217-21. PubMed ID: 8916174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
    Smith SR; Stenlof KS; Greenway FL; McHutchison J; Schwartz SM; Dev VB; Berk ES; Kapikian R
    Obesity (Silver Spring); 2011 Sep; 19(9):1796-803. PubMed ID: 21720429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
    Wang X; Chen J; Li L; Zhu CL; Gao J; Rampersad S; Bu L; Qu S
    Lipids Health Dis; 2017 Apr; 16(1):70. PubMed ID: 28376799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hypothalamic obesity with caffeine and ephedrine.
    Greenway FL; Bray GA
    Endocr Pract; 2008 Sep; 14(6):697-703. PubMed ID: 18996788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ephedrine, caffeine and aspirin promote weight loss in obese subjects.
    Krieger DR; Daly PA; Dulloo AG; Ransil BJ; Young JB; Landsberg L
    Trans Assoc Am Physicians; 1990; 103():307-12. PubMed ID: 2132541
    [No Abstract]   [Full Text] [Related]  

  • 40. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.
    Brinkoetter M; Magkos F; Vamvini M; Mantzoros CS
    Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E99-E104. PubMed ID: 21505147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.